Brief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
14/10/2026 22:02
BRIEF-Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics Oct 14 (Reuters) - Lakefront Biotherapeutics NV LKFT.AS:
LAKEFRONT ANNOUNCES SALE OF PRECLINICAL CAR-T PROGRAMS TO ARMED CELL THERAPEUTICS
LAKEFRONT BIOTHERAPEUTICS NV: ARMED CELL THERAPEUTICS TO INDEPENDENTLY ADVANCE BOUGHT CELL THERAPY PROGRAMS
LAKEFRONT BIOTHERAPEUTICS NV: TERMS OF DEAL INCLUDE UPFRONT PAYMENT OF EUR 8 MILLION & POTENTIAL FOR UP TO $230 MILLION IN MILESTONE PAYMENTS
LAKEFRONT BIOTHERAPEUTICS NV: INTENTION TO WIND DOWN CELL THERAPY ACTIVITIES AFTER REVIEW OF STRATEGIC ALTERNATIVES IS SUBSTANTIALLY COMPLETE
Source text: ID:nGNX7pxx9m
Further company coverage: LKFT.AS
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline